8-K Announcements
6Material company update
Dec 9, 2025·SEC
Material company update
Dec 3, 2025·SEC
Material company update
Oct 9, 2025·SEC
Akero Therapeutics, Inc.(AKRO)Earnings, Financials & Key Ratios
AKRO•NASDAQ
Price updated Apr 24, 2026
AboutAkero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Show more
- Revenue$0
- EBITDA-$285M-65.1%
- Net Income-$252M-66.1%
- EPS (Diluted)-3.75-29.8%
- ROE-39.22%-11.4%
AKRO Key Insights
Akero Therapeutics, Inc. (AKRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 27.7% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when AKRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AKRO Price & Volume
Akero Therapeutics, Inc. (AKRO) stock price & volume — 10-year historical chart
Loading chart...
AKRO Growth Metrics
Akero Therapeutics, Inc. (AKRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-23.44%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM0.27%
Return on Capital
10 Years-167.81%
5 Years-42.85%
3 Years-42.06%
Last Year-42.37%
AKRO Recent Earnings
Akero Therapeutics, Inc. (AKRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)
Q4 2025Latest
Nov 7, 2025Metric
Actual
Est
EPS
$0.99-5.3%
$0.94
Rev
—
—
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.86+11.3%
$0.97
Rev
—
—
Q2 2025
May 12, 2025Metric
Actual
Est
EPS
$0.90+189.1%
$1.01
Rev
—
—
Q1 2025
Feb 28, 2025Metric
Actual
Est
EPS
$0.99-1.0%
$0.98
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q4 2025Latest | Nov 7, 2025 | $0.99vs $0.94-5.3% | — |
| Q3 2025 | Aug 8, 2025 | $0.86vs $0.97+11.3% | — |
| Q2 2025 | May 12, 2025 | $0.90vs $1.01+189.1% | — |
| Q1 2025 | Feb 28, 2025 | $0.99vs $0.98-1.0% | — |
Based on last 12 quarters of dataView full earnings history →
AKRO Peer Comparison
Akero Therapeutics, Inc. (AKRO) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ELVN | 2.75B | 45.10 | -24.64 | -21.04% | 0.00 | |||
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 GPCR | 2.56B | 44.51 | -18.55 | -15.14% | 0.00 | |||
 TERN | 4.77B | 52.95 | -51.41 | -20.02% | 0.00 | |||
 VKTX | 3.52B | 30.38 | -9.52 | -71.31% | 0.00 | |||
 ALDX | 118.23M | 1.96 | -3.50 | -0% | 0.35 |
Compare AKRO vs Peers
Akero Therapeutics, Inc. (AKRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AKRO Income Statement
Akero Therapeutics, Inc. (AKRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 213K | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | -213K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | 100% | - | - | - | - |
Operating Expenses | 4.56M | 13.78M | 45.65M | 80.15M | 100.89M | 115.16M | 172.87M | 285.42M | 330.02M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 1.08M | 1.9M | 8.61M | 15.24M | 19.13M | 29.87M | 31.07M | 37.93M | 43.02M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 3.49M | 11.88M | 37.05M | 64.92M | 81.76M | 85.28M | 141.8M | 247.5M | 287M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -4.56M▲ 0% | -13.78M▼ 201.9% | -45.65M▼ 231.3% | -80.15M▼ 75.6% | -100.89M▼ 25.9% | -115.16M▼ 14.1% | -172.87M▼ 50.1% | -285.42M▼ 65.1% | -330.02M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | -201.88% | -231.33% | -75.58% | -25.87% | -14.14% | -50.12% | -65.11% | - |
EBITDA | 414.91K | 0 | -45.76M | -79.94M | -100.84M | -115.11M | -172.84M | -285.4M | -318.45M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -100% | - | -74.72% | -26.15% | -14.15% | -50.15% | -65.13% | -18.27% |
D&A (Non-Cash Add-back) | 4.98M | 13.78M | -104K | 213K | 41K | 43K | 29K | 18K | 24K |
EBIT | -4.56M | -81.71M | -43.73M | -79.21M | -100.78M | -111.29M | -148.66M | -247.39M | -288.2M |
Net Interest Income | 0 | 0 | 1.9M | 947K | 109K | 3.12M | 21.11M | 33.36M | 27.43M |
Interest Income | 0 | 0 | 1.9M | 947K | 109K | 3.86M | 24.21M | 38.03M | 32.05M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 739K | 3.1M | 4.67M | 4.62M |
Other Income/Expense | 0 | -67.94M | 1.9M | 947K | 109K | 3.12M | 21.11M | 33.36M | 37.2M |
Pretax Income | -4.56M▲ 0% | -81.71M▼ 1690.4% | -43.76M▲ 46.5% | -79.21M▼ 81.0% | -100.78M▼ 27.2% | -112.03M▼ 11.2% | -151.76M▼ 35.5% | -252.06M▼ 66.1% | -292.82M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | -17K | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0.02% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.56M▲ 0% | -81.71M▼ 1690.4% | -43.76M▲ 46.5% | -79.19M▼ 81.0% | -100.78M▼ 27.3% | -112.03M▼ 11.2% | -151.76M▼ 35.5% | -252.06M▼ 66.1% | -292.82M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -1690.4% | 46.45% | -80.98% | -27.26% | -11.17% | -35.46% | -66.09% | -23.44% |
Net Income (Continuing) | -4.56M | -81.71M | -43.76M | -79.19M | -100.78M | -112.03M | -151.76M | -252.06M | -292.82M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.16▲ 0% | -3.85▼ 2306.3% | -2.90▲ 24.7% | -2.52▲ 13.1% | -2.89▼ 14.7% | -2.87▲ 0.7% | -2.89▼ 0.7% | -3.75▼ 29.8% | -3.57▲ 0% |
EPS Growth % | - | -2306.25% | 24.68% | 13.1% | -14.68% | 0.69% | -0.7% | -29.76% | 0.27% |
EPS (Basic) | -0.16 | -3.85 | -2.90 | -2.52 | -2.89 | -2.87 | -2.89 | -3.75 | - |
Diluted Shares Outstanding | 28.56M | 21.22M | 15.07M | 31.46M | 34.83M | 38.98M | 52.57M | 67.14M | 82.01M |
Basic Shares Outstanding | 28.56M | 21.22M | 15.07M | 31.46M | 34.83M | 38.98M | 52.57M | 67.14M | 82.01M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
AKRO Balance Sheet
Akero Therapeutics, Inc. (AKRO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 638K | 77.13M | 138.05M | 271.35M | 193.58M | 355.17M | 559.96M | 770.38M | 754.53M |
Cash & Short-Term Investments | 598K | 75.97M | 136.4M | 268.39M | 188.26M | 351.45M | 550.01M | 743.08M | 737.83M |
Cash Only | 598K | 75.97M | 64.79M | 187.24M | 150.48M | 249.77M | 234.21M | 340.24M | 176.03M |
Short-Term Investments | 0 | 0 | 71.61M | 81.14M | 37.77M | 101.68M | 315.8M | 402.84M | 561.79M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | 40K | 1.16M | 0 | 0 | 0 | 0 | 9.95M | 27.3M | 16.71M |
Total Non-Current Assets | 20K | 20K | 69K | 1.99M | 1.97M | 1.4M | 20.31M | 55.51M | 251.04M |
Property, Plant & Equipment | 0 | 0 | 0 | 1.79M | 1.55M | 1.29M | 1.03M | 755K | 552K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 20K | 20K | 0 | 0 | 0 | 0 | 19.28M | 54.75M | 1.09B |
Other Non-Current Assets | 0 | 0 | 69K | 201K | 417K | 108K | 0 | 0 | 0 |
Total Assets | 658K▲ 0% | 77.15M▲ 11625.1% | 138.12M▲ 79.0% | 273.34M▲ 97.9% | 195.55M▼ 28.5% | 356.57M▲ 82.3% | 580.27M▲ 62.7% | 825.89M▲ 42.3% | 1.01B▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 11625.08% | 79.02% | 97.9% | -28.46% | 82.34% | 62.74% | 42.33% | 120.25% |
Total Current Liabilities | 222K | 2.34M | 9.37M | 13.11M | 25.13M | 19.08M | 19.13M | 39.75M | 47.65M |
Accounts Payable | 60K | 1.37M | 947K | 3.43M | 6.71M | 7.97M | 7.04M | 9.03M | 20.4M |
Days Payables Outstanding | - | - | - | 5.87K | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 875K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2K | 665K | 1.61M | 495K | 554K | 9.99M | 1.3M | 1.17M | 21.4M |
Current Ratio | 2.87x | 32.93x | 14.73x | 20.70x | 7.70x | 18.61x | 29.27x | 19.38x | 15.83x |
Quick Ratio | 2.87x | 32.93x | 14.73x | 20.70x | 7.70x | 18.61x | 29.27x | 19.38x | 15.83x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 5M | 124.73M | 23K | 1.52M | 1.31M | 10.93M | 25.84M | 36.02M | 289K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 9.54M | 24.96M | 35.3M | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 1.52M | 1.31M | 1.08M | 819K | 529K | 1.64M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5M | 124.73M | 23K | 0 | 0 | 305K | 54K | 194K | 0 |
Total Liabilities | 5.22M | 127.07M | 9.39M | 14.63M | 26.44M | 30.01M | 44.97M | 75.77M | 47.94M |
Total Debt | 0 | 0 | 85K | 1.81M | 1.52M | 10.95M | 26.3M | 36.46M | 1.16M |
Net Debt | -598K | -75.97M | -64.7M | -185.43M | -148.97M | -238.83M | -207.9M | -303.78M | -174.87M |
Debt / Equity | - | - | 0.00x | 0.01x | 0.01x | 0.03x | 0.05x | 0.05x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | -1.44x | - | - | - | - | - | - | - | 0.55x |
Interest Coverage | - | - | - | - | - | -155.83x | -55.78x | -61.14x | -62.41x |
Total Equity | -4.56M▲ 0% | -49.92M▼ 993.8% | 128.73M▲ 357.9% | 258.71M▲ 101.0% | 169.11M▼ 34.6% | 326.56M▲ 93.1% | 535.31M▲ 63.9% | 750.11M▲ 40.1% | 957.64M▲ 0% |
Equity Growth % | - | -993.76% | 357.87% | 100.98% | -34.63% | 93.11% | 63.92% | 40.13% | 126.45% |
Book Value per Share | -0.16 | -2.35 | 8.54 | 8.22 | 4.86 | 8.38 | 10.18 | 11.17 | 11.68 |
Total Shareholders' Equity | -4.56M | -49.92M | 128.73M | 258.71M | 169.11M | 326.56M | 535.31M | 750.11M | 957.64M |
Common Stock | 0 | 0 | 3K | 4K | 4K | 5K | 6K | 7K | 8K |
Retained Earnings | -4.56M | -86.56M | -130.32M | -209.53M | -310.3M | -422.34M | -574.1M | -826.16M | -1.05B |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -6K | -3K | -27K | 37K | 270K | 948K | 1.83M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AKRO Cash Flow Statement
Akero Therapeutics, Inc. (AKRO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.38M | -4.63M | -35.63M | -70.8M | -79.68M | -92.52M | -145.37M | -230.11M | -250.17M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | -5.55% | -670.31% | -98.74% | -12.54% | -16.11% | -57.12% | -58.29% | -109.88% |
Net Income | -4.56M | -81.71M | -43.76M | -79.21M | -100.78M | -112.03M | -151.76M | -252.06M | -292.82M |
Depreciation & Amortization | 0 | 0 | -104K | 17K | 41K | 43K | 29K | 18K | -4.76M |
Stock-Based Compensation | 0 | 121K | 1.77M | 6.02M | 10.05M | 23.24M | 21.5M | 29.7M | 34.28M |
Deferred Taxes | 0 | 0 | 104K | 83K | 1.07M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -60K | 75.91M | -104K | 196K | 203K | 689K | -8.46M | -10.76M | 3.44M |
Working Capital Changes | 182K | 1.06M | 6.46M | 2.08M | 9.73M | -4.46M | -6.67M | 3M | 9.69M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 60K | 1.31M | -426K | 2.48M | 3.27M | 968K | -645K | 2.01M | -11.91M |
Cash from Investing | 0 | -5M | -71.51M | -9.76M | 42.28M | -63.83M | -223.62M | -109.71M | -330.79M |
Capital Expenditures | 0 | -5M | 0 | -148K | 0 | 0 | 0 | -999K | 0 |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 9.61K | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -5K | 0 | -9.61K | 0 | 0 | 0 | 0 | 56.78M |
Cash from Financing | 5M | 85.01M | 95.99M | 203.11M | 602K | 255.63M | 353.32M | 445.85M | 440.93M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 10M | 15M | 10M | 0 |
Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 602K | 1000K | 1000K | 1000K | 3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 5M | -493K | 536K | 553K | 0 | 4.43M | 2.89M | 12.77M | -25.67M |
Net Change in Cash | 618K▲ 0% | 75.38M▲ 12097.7% | -11.15M▼ 114.8% | 122.54M▲ 1198.8% | -36.8M▼ 130.0% | 99.29M▲ 369.8% | -15.67M▼ 115.8% | 106.03M▲ 776.5% | -140.03M▲ 0% |
Free Cash Flow | -4.38M▲ 0% | -9.63M▼ 119.6% | -35.63M▼ 270.2% | -70.95M▼ 99.2% | -79.68M▼ 12.3% | -92.52M▼ 16.1% | -145.37M▼ 57.1% | -231.11M▼ 59.0% | -250.17M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | -119.65% | -270.15% | -99.15% | -12.3% | -16.11% | -57.12% | -58.98% | -17.65% |
FCF per Share | -0.15 | -0.45 | -2.36 | -2.26 | -2.29 | -2.37 | -2.77 | -3.44 | -3.05 |
FCF Conversion (FCF/Net Income) | 0.96x | 0.06x | 0.81x | 0.89x | 0.79x | 0.83x | 0.96x | 0.91x | 0.85x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.98M | 2.27M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
AKRO Key Ratios
Akero Therapeutics, Inc. (AKRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -111.04% | -40.88% | -47.11% | -45.2% | -35.22% | -39.22% | -30.58% |
Return on Invested Capital (ROIC) | - | - | -87.57% | -161.98% | -160.12% | -62.46% | -55.33% | -32.93% |
Debt / Equity | - | 0.00x | 0.01x | 0.01x | 0.03x | 0.05x | 0.05x | 0.00x |
Interest Coverage | - | - | - | - | -155.83x | -55.78x | -61.14x | -62.41x |
FCF Conversion | 0.06x | 0.81x | 0.89x | 0.79x | 0.83x | 0.96x | 0.91x | 0.85x |
Related:AKRO Dividend History·AKRO Revenue History·AKRO Price History·AKRO P/E History·AKRO Financial Ratios·AKRO Institutional Holders
AKRO SEC Filings & Documents
Akero Therapeutics, Inc. (AKRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
AKRO Frequently Asked Questions
Akero Therapeutics, Inc. (AKRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Akero Therapeutics, Inc. (AKRO) grew revenue by 0.0% over the past year. Growth has been modest.
Akero Therapeutics, Inc. (AKRO) reported a net loss of $292.8M for fiscal year 2024.
Dividend & Returns
Akero Therapeutics, Inc. (AKRO) has a return on equity (ROE) of -39.2%. Negative ROE indicates the company is unprofitable.
Akero Therapeutics, Inc. (AKRO) had negative free cash flow of $250.2M in fiscal year 2024, likely due to heavy capital investments.